Resistance mechanisms and the future of bacterial enoyl-acyl carrier protein reductase (FabI) antibiotics

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 3, 2016, Pages

  Yao, Jiangwei ^a   Rock, Charles O ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CELL PROTEIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADPH); ANTIINFECTIVE AGENT; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH);

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; HUMAN; HYPOTHESIS; MISSENSE MUTATION; NONHUMAN; ANTAGONISTS AND INHIBITORS; GENETICS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); HUMANS; MUTATION, MISSENSE;

EID: 84959528554     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a027045     Document Type: Article

References (71)

1. Bernstein J, Lott WA, Steinberg BA, Yale HL. 1952. Chemotherapy of experimental tuberculosis. V: Isonicotinic acid hydrazide (nydrazid) and related compounds. Am Rev Tuberc 65: 357-364.
2. Blaser MJ, Falkow S. 2009.What are the consequences of the disappearing human microbiota? Nat Rev Micro 7: 887-894.
3. Boursi B, Mamtani R, Haynes K, Yang YX. 2015. The effect of past antibiotic exposure on diabetes risk. Eur J Endocrinol 172: 639-648.
4. Brenwald NP, Fraise AP. 2003. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). JHosp Infect 55: 141-144.
5. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458: 83-86.
6. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80: 62-73.
7. Campbell JW, Cronan JE Jr. 2001. Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery. Annu Rev Microbiol 55: 305-332.
8. Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, et al. 2012. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488: 621-626.
9. Croswell A, Amir E, Teggatz P, Barman M, Salzman NH. 2009. Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection. Infect Immun 77: 2741-2753.
10. Curiao T, Marchi E, Viti C, Oggioni MR, Baquero F, Martinez JL, Coque TM. 2015. Polymorphic variation in susceptibility and metabolism of triclosan-resistant mutants of Escherichia coli and Klebsiella pneumoniae clinical strains obtained after exposure to biocides and antibiotics. Antimicrobiol Agents Chem 59: 3413-3423.
11. David HL. 1970. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 20: 810-814.
12. Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, Moreau F, Vongsouthi V, Maher K, Morrissey I, et al. 2011. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother 55: 4692-4697.
13. Fan F, Yan K, Wallis NG, Reed S, Moore TD, Rittenhouse SF, De Wolf JW Jr, Huang J, McDevitt D, Miller WH, et al. 2002. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 46: 3343-3347.
14. Hazbón MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, et al. 2006. Population genetics study of Isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrobiol Agents Chem 50: 2640-2649.
15. Heath RJ, Rock CO. 1995. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J Biol Chem 270: 26538-26542.
16. Heath RJ, Rock CO. 1996. Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli. J Biol Chem 271: 1833-1836.
17. Heath RJ, Rock CO. 2000. A triclosan-resistant bacterial enzyme. Nature 406: 145-146.
18. Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO. 1998. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J Biol Chem 273: 30316-30321.
19. Heath RJ, Rubin JR, Holland DR, Zhang E, Snow ME, Rock CO. 1999.Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J Biol Chem 274: 11110-11114.
20. Heath RJ, Su N, Murphy CK, Rock CO. 2000. The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis. J Biol Chem 275: 40128-40133.
21. Heath RJ, White SW, Rock CO. 2001. Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res 40: 467-497.
22. Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, Dorsey M, Hafkin B, Ramnauth J, Romanov V, et al. 2012. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother 56: 5865-5874.
23. Kaplan N, Awrey D, Bardouniotis E, Berman J, Yethon J, Pauls HW, Hafkin B. 2013a. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. J Chemother 25: 18-25.
24. Kaplan N, Garner C, Hafkin B. 2013b. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Eur J Pharm Sci 50: 440-446.
25. Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, Zhanel GG. 2007. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 51: 1580-1581.
26. Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG. 2009. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother 53: 3544-3548.
27. Lee JH, Ammerman NC, Nolan S, Geiman DE, Lun S, Guo H, Bishai WR. 2012. Isoniazid resistancewithout a loss of fitness in Mycobacterium tuberculosis. Nat Commun 3: 753.
28. Levy CW, Roujeinikova A, Sedelnikova S, Baker PJ, Stuitje AR, Slabas AR, Rice DW, Rafferty JB. 1999. Molecular basis of triclosan activity. Nature 398: 383-384.
29. Lu H, Tonge PJ. 2010. Drug-target residence time: Critical information for lead optimization. Curr Opin Chem Biol 14: 467-474.
30. Mårild K, Ye W, Lebwohl B, Green PH, Blaser MJ, Card T, Ludvigsson JF. 2013. Antibiotic exposure and the development of coeliac disease: A nationwide case-control study. BMC Gastroenterol 13: 109.
31. Marrakchi H, DeWolf C Jr, Quinn C, West J, Polizzi BJ, So CY, Holmes DJ, Reed SL, Heath RJ, Payne DJ, et al. 2003. Characterization of Streptococcus pneumoniae enoyl-[ acyl carrier protein] reductase (FabK). Biochem J 370: 1055-1062.
32. Marrakchi H, Lanéelle MA, Daffé M. 2014. Mycolic acids: Structures, biosynthesis, and beyond. Chem Biol 21: 67-85.
33. Massengo-Tiasse RP, Cronan JE. 2008. Vibrio cholerae fabV defines a new class of enoyl acyl-carrier-protein reductase. J Biol Chem 283: 1308-1316.
34. McMurry LM, Oethinger M, Levy S. 1998a. Triclosan targets lipid synthesis. Nature 394: 531-532.
35. McMurry LM, Oethinger M, Levy SB. 1998b. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol Lett 166: 305-309.
36. Meyerovich M, Mamou G, Ben-Yehuda S. 2010. Visualizing high error levels during gene expression in living bacterial cells. Proc Natl Acad Sci 107: 11543-11548.
37. O’Sullivan DM, McHugh TD, Gillespie SH. 2010. Mapping the fitness of Mycobacterium tuberculosis strains: A complex picture. J Med Microbiol 59: 1533-1535.
38. Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH. 2007a. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother 60: 568-574.
39. Park HS, Yoon YM, Jung SJ, Yun IN, Kim CM, Kim JM, Kwak JH. 2007b. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. Int J Antimicrob Agents 30: 446-451.
40. Parsons JB, Rock CO. 2011. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr Opin Microbiol 14: 544-549.
41. Parsons JB, Rock CO. 2013. Bacterial lipids:Metabolism and membrane homeostasis. Prog Lipid Res 52: 249-276.
42. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. 2011.Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci 108: 15378-15383.
43. Parsons JB, Frank MW, Rosch JW, Rock CO. 2013a. Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice. Antimicrob Agents Chemother 57: 5729-5732.
44. Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO. 2013b. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother 57: 2182-2190.
45. Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf JW Jr, Fosberry AP, Greenwood R, Head MS, et al. 2002. Discovery of a novel and potent class of FabIdirected antibacterial agents. Antimicrob Agents Chemother 46: 3118-3124.
46. Pinto L, Menzies D. 2011. Treatment of drug-resistant tuberculosis. Infect Drug Resist 4: 129-135.
47. Quemard A, Sacchettini JC, Dessen A, Vilchèze C, Bittman R, Jacobs WR, Blanchard JS. 1995. Enzymic characterization of the target for Isoniazid inMycobacterium tuberculosis. Biochemistry 34: 8235-8241.
48. Rawat R, Whitty A, Tonge PJ. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. ProcNatl Acad Sci 100: 13881-13886.
49. Rock CO, Jackowski S. 2002. Forty years of fatty acid biosynthesis. Biochem Biophys Res Commun 292: 1155-1166.
50. Rosner JL, Storz G. 1994. Effects of peroxides on susceptibilities of Escherichia coli and Mycobacterium smegmatis to isoniazid. Antimicrobiol Agents Chem 38: 1829-1833.
51. Russell AD. 2003. Similarities and differences in the responses of microorganisms to biocides. J Antimicrob Chemother 52: 750-763.
52. Russell AD. 2004. Whither triclosan? J Antimicrob Chemother 53: 693-695.
53. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. 2015. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: A systematic review. PLoS ONE 10: e0119628.
54. Silver LL. 2007. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6: 41-55.
55. Silver LL. 2011. Challenges of antibacterial discovery. Clin Microbiol Rev 24: 71-109.
56. Silver LL, Bostian KA. 1993. Discovery and development of new antibiotics: The problem of antibiotic resistance. Antimicrob Agents Chemother 37: 377-383.
57. Skovgaard S, Nielsen LN, Larsen MH, Skov RL, Ingmer H, Westh H. 2013. Staphylococcus epidermidis isolated in 1965 are more susceptible to Triclosan than current isolates. PLoS ONE 8: e62197.
58. Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser JM. 1997. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptibleMycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrobiol Agents Chem 41: 600-606.
59. Stewart MJ, Parikh S, Xiao G, Tonge PJ, Kisker C. 1999. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J Mol Biol 290: 859-865.
60. van Soolingen D, de Haas PEW, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. 2000.Mutations at amino acid position 315 of the katG gene are associated with highlevel resistance to Isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182: 1788-1790.
61. Vilchèze C, Jacobs WR Jr. 2007. The mechanism of Isoniazid killing: Clarity through the scope of genetics. Annu Rev Microbiol 61: 35-50.
62. Vilchèze C, Weisbrod TR, Chen B, Kremer L, Hazbón MH, Wang F, Alland D, Sacchettini JC, Jacobs WR. 2005. Altered NADH/NADþ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrobiol Agents Chem 49: 708-720.
63. Vilchèze C, Wang F, Arai M, Hazbon MH, Colangeli R, Kremer L, Weisbrod TR, Alland D, Sacchettini JC, Jacobs WR. 2006. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12: 1027-1029.
64. Walkup GK, You Z, Ross PL, Allen EK, Daryaee F, Hale MR, O’Donnell J, Ehmann DE, Schuck VJ, Buurman ET, et al. 2015. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nat Chem Biol 11: 416-423.
65. Wengenack NL, Todorovic S, Yu L, Rusnak F. 1998. Evidence for differential binding of isoniazid by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T). Biochemistry 37: 15825-15834.
66. Xu H, Sullivan TJ, Sekiguchi J, Kirikae T, Ojima I, Stratton CF, Mao W, Rock FL, Alley MR, Johnson F, et al. 2008. Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus. Biochemistry 47: 4228-4236.
67. Yao J, Rock CO. 2015. How bacterial pathogens eat host lipids: Implications for the development of fatty acid synthesis therapeutics. J Biol Chem 290: 5940-5946.
68. Yao J, Maxwell JB, Rock CO. 2013. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J Biol Chem 288: 36261-36271.
69. Zhang YM, Rock CO. 2008.Membrane lipid homeostasis in bacteria. Nat Rev Microbiol 6: 222-233.
70. Zhang YM, White SW, Rock CO. 2006. Inhibiting bacterial fatty acid synthesis. J Biol Chem 281: 17541-17544.
71. Zhu L, Lin J, Ma J, Cronan JE, Wang H. 2010. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. Antimicrobiol Agents Chem 54: 689-698.